Sun, Sep 21, 2014, 9:03 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

J. C. Penney Company, Inc. Message Board

lu.madar87 180 posts  |  Last Activity: Jan 11, 2014 10:34 AM Member since: Sep 21, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    JCP and Sears

    by yahutag Jan 11, 2014 9:46 AM
    lu.madar87 lu.madar87 Jan 11, 2014 10:34 AM Flag

    Sears is now the underdog and JCP is taking their customers and market share -- so true.
    While it's trading more than 5X JCP's price.
    Sears only managed to show profits so far by slashing overhead in employees and stores, and not improving the stores they kept but it can't keep doing that.

    One way CEO Johnson blew so much money was renovating JCP stores so now they're generally very nice, a pleasant shopping experience while Sears is dumpy. Johnson also blew off the traditional JCP shopper.

    Now shoppers are back, the stores are nice and JCP is doing better than its competitors.
    The bears would like to twist it otherwise but this is IT for the bottom, going up from here.

    Sentiment: Strong Buy

  • lu.madar87 lu.madar87 Jan 9, 2014 6:46 AM Flag

    With the financial media especially biased opinion blogs like the Fool, Seeking Alpha and assorted reports from Down Jones to WSJ skewing the comment from JCP way out of context to suit their aggressive bear tactics -- so many options turning to dust with JCP chugging away stronger -- it is easy to shake out the weak hands here. Their loss.

    Investors have to realize what's happening here, don't throw away your shares in panic.

    Fact is almost ALL retailers missed the analyst "targets" for the holiday season, thanks to competitive pricing which kept revenues lower although buying stayed high. But in JCP's case there was major improvement YtoY, QtoQ, and luring former customers BACK to the stores and online has been half the battle and will continue to pay off better and better as more old inventory is replaced by higher-profit margin merchandise.

    Even if it's true that shooting to over $10.00 in Nov./ up 10% on the Nov. numbers report might have been too much too fast, trading around $9.50 was correction enough --
    yesterday was sheer headline-driven manipulation and excessive cynicism.

    This upgrade is right: 2014 will be a good year!

    Sentiment: Strong Buy

  • lu.madar87 lu.madar87 Jan 9, 2014 6:13 AM Flag

    And $11.00 price target. This guy thinks like I do, why I loaded more at $7.50, the AH buys were a steal:

    J. C. Penney Company, Inc. (JCP)
    -NYSE

    7.37 Down 0.82(10.01%) Jan 8, 4:01PM EST|Pre-Market : 7.72 Up 0.35 (4.75%) 6:00AM EST - Nasdaq Real Time Price
    Add to Portfolio
    Prev Close: 8.19
    Open: 7.50

    Bid: 7.72 x 2600
    Ask: 7.78 x 300

    1y Target Est: 10.03
    Beta: 1.23
    Earnings Date: Feb 24 - Feb 28 (Est.)
    Day's Range: 7.36 - 7.69
    52wk Range: 6.24 - 23.10
    Volume: 77,130,898
    Avg Vol (3m): 34,723,500
    Market Cap: 2.25B
    P/E (ttm): N/A
    EPS (ttm):

    Sentiment: Buy

  • lu.madar87 lu.madar87 Jan 8, 2014 7:41 PM Flag

    exactly -- it made all the targets, can't be blamed on what happened in the past, even the worst critics like the guy who wrote this afternoon's FOOL article have to admit that -- then look for excuses to bash the stock.

    JCP did meet targets: maybe there will be no "earnings surprises" but that has already been MORE THAN factored into the dip into the low 8's, today was ridiculous. HOLDING AH, smart money sees it's a cheap buy up.

    From the FOOL:

    To its credit, J.C. Penney did reiterate existing Q4 guidance, which most notably called for comparable-store sales and gross margin to improve sequentially and year over year.

    But it didn't exactly set a high bar considering that last year's results were horrendous. What's more, shares of J.C. Penney fell by more than 4% after it told investors that November's same-store sales rose 10.1%. And that increase would have been fine, except most analysts were already hoping J.C. Penney would report double-digit comps in November, anyway.

    In addition, while the guidance also called for total available liquidity to be "in excess of $2 billion at year end," that served as little solace for investors whose stakes were diluted by 38% in Q3 thanks to the company's massive secondary stock offering, through which Goldman Sachs helped it sell 84 million shares at below-market prices.

    Sentiment: Strong Buy

  • Even this afternoon's FOOL article by someone probably short on JCP and fooling the public himself with scare tactics based on the fact that CEO Ullman allegedly did fool investors just B4 the public offering, and b/c the run-up in Nov. to $10.oo maybe was too much at once, admits JCP IS DOING BETTER QUARTER BY QUARTER, YEAR BY YEAR, IS RIGHT ON TARGET -- and NEXT YEAR WILL BE BETTER AND BETTER.

    Can't blame JCP's current management and numbers for the lousy comp's during the "RJ era." This article like others is NOT based on any substance -- just griping that numbers may not have been spectacular.
    -- Also keep in mind; IF THE NUMBERS WERE TRULY POOR JCP WOULDN'T RISK LOOKING LIKE A FOOL BY SAYING THEY WERE "PLEASED" WITH THEM. The only FOOL is the Motley Fool and cohorts.

    To its credit, J.C. Penney did reiterate existing Q4 guidance, which most notably called for comparable-store sales and gross margin to improve sequentially and year over year.

    But it didn't exactly set a high bar considering that last year's results were horrendous. What's more, shares of J.C. Penney fell by more than 4% after it told investors that November's same-store sales rose 10.1%. And that increase would have been fine, except most analysts were already hoping J.C. Penney would report double-digit comps in November, anyway.

    In addition, while the guidance also called for total available liquidity to be "in excess of $2 billion at year end," that served as little solace for investors whose stakes were diluted by 38% in Q3 thanks to the company's massive secondary stock offering, through which Goldman Sachs helped it sell 84 million shares at below-market prices.

    Sentiment: Strong Buy

  • With FDA approval, which is likely b/c the new CEO is presumably more competent working with the FDA,
    price should at least double. PRICE HOLDING STEADY AT $2.00 SUPPORT TODAY.

    This is important for the company as an SPA designation basically entails that if a company executes a trial exactly as it promises it will, and the data is presented as asked for by the FDA, the drug would receive regulatory approval. In this case, receiving ANCHOR approval means the potential to make much more money with the drug.

    The FDA is bound to honor an SPA agreement once the Phase III trial is completed, as long as the company has followed the agreed-upon protocol to the letter, and efficacy and safety is shown in the data, as agreed upon with the FDA.

    Herein lies the problem with Amarin, and not with the FDA, as many Amarin investors believe. We have continually informed our followers that we were bearish on Amarin because of its poor management. Having the SPA agreement revoked shows us that Amarin did not follow the agreement as guided by the FDA, and/or simply did not know how to properly communicate with the organization; not some "conspiracy" enacted upon by the FDA to cheat Amarin on the behalf of "big pharma" to stop the drug from receiving the ANCHOR approval.

    It's also hopeful news for Amarin investors that Joseph S. Zakrzewski has stepped down as company CEO, who has been the main reason for Amarin's failures in our strong opinion -- simply stated, we feel Zakrzewski was a poor CEO.

    If Amarin's new CEO John F. Thero conveys the SPA case correctly to the FDA, it's a good chance the agreement will be reinstated, which would lead to eventual approval for the ANCHOR indication. If this turns out to be the case, Amarin should at least double in price from its current valuation.

    We feel Amarin is undervalued here, and should be currently valued closer to a $500M market cap, simply on the fact that Zakrzewski is no longer the captain of what has been a sinking ship.

    The F

  • lu.madar87 lu.madar87 Jan 2, 2014 8:04 PM Flag

    According to Barchart: 2.01 low resistance, 2.05 higher resistance -- IF there's no news or investor sentiment one way or the other. Fact that this dipped lower during the day on no news but higher EOD means it is staying at this level min., should touch well above $2.00:

    STARTED OUT $2.07 IN FRANKFORT TODAY UNTIL THEY FOLLOWED OUR LEAD AND DROPPED DOWN...THE WHOLE US MARKET WAS DOWN.

  • Reply to

    Down to 1.91 AH

    by twocornfused Jan 2, 2014 4:11 PM
    lu.madar87 lu.madar87 Jan 2, 2014 6:39 PM Flag

    And BTW what's with "twocornfused" who posted this in the place? Is he a couple of fused ears of corn? Someone who posts with such a handle without proof-reading needs to stop and chill.

  • Reply to

    Down to 1.91 AH

    by twocornfused Jan 2, 2014 4:11 PM
    lu.madar87 lu.madar87 Jan 2, 2014 6:37 PM Flag

    Like others have said it's upto 195 Bid again, today's low WAS a joke and MM manipulation for their hedge fund buddies and those in the know: looks to me like this will have good news any day now before 1/15, this yo-yo is just so they can make a few bucks along the way and shake out the weak hands. Frustrating yes.

    But look how quickly the FDA responded on ARIA a couple weeks ago, caught those who were playing the up-down game to make a few bucks by surprise, and they lost the big money.
    Remember the FDA may respond any time before the 15th and like with ARIA's Iclusig will likely allow Vascepta sales but with a "black box" warning with more indications and that it's no magic pill yada yada.

    Sentiment: Strong Buy

  • Reply to

    FDA - Jan 15

    by rafunrafun Dec 31, 2013 8:49 AM
    lu.madar87 lu.madar87 Dec 31, 2013 9:16 AM Flag

    I agree: the FDA will likely reinstate SPA but with a broader warning label, like in other similar cases
    e.g. Aria, although a significant difference is there here unlike with Aria's Iclusig which has proven potentially dangerous side-effects (BUT is life-saving for many patients who gladly take those risks) Amarin's fish oil product has no negative side-effects nor are any claimed: it's that benefits are not proven to the FDA's satisfaction, so some qualifiers are needed. I frankly think that's fair,
    as a balance between not erring on the side of pulling a useful medicine off the shelves vs.
    giving people the impression that taking a tablet will somehow "cure" very high triglycerides.
    It's LIKELY to help along with life-style and diet changes.

    Still that would increase the market ten-fold, I'm all IN.

    That seems to be the feeling of investors: Bid and Pre-Market price was UP as 1/15 approaches.

    The latest analyst estimates are that shares could be valued at $8.00 if that's the case.

    Sentiment: Strong Buy

  • Reply to

    Looks like no tax-loss selling

    by fsulevine Dec 30, 2013 4:23 PM
    lu.madar87 lu.madar87 Dec 31, 2013 8:05 AM Flag

    Duh, but it matters how you write it off, that's the point of tax-selling: short or long-term.
    You should know what you're talking about B4 you "correct" someone, can't believe you have 6 like-minded likes who know as little as you...guess you don't invest enough for it to matter but it sure does to serious investors.

  • Reply to

    Looks like no tax-loss selling

    by fsulevine Dec 30, 2013 4:23 PM
    lu.madar87 lu.madar87 Dec 30, 2013 4:35 PM Flag

    tax-loss selling already occurred with 3 days to settle by EOY, now there's anticipation of possible good news, and short covering -- the trend was well up today and ended going higher into tomorrow. Will go
    above $2.00 very early on.

    Sentiment: Buy

  • Reply to

    ihub is on fire w/ articles

    by cincyreds57 Dec 28, 2013 11:54 AM
    lu.madar87 lu.madar87 Dec 28, 2013 1:22 PM Flag

    You are clearly ignorant and spreading false info about iHub so it's a good thing you're too dumb to have figured out that anyone can sign up for free and then post.

    You and the other dummies keep the low IQ-bunch mostly on Yahoo but at least we can filter you out.

    Only thing you have to pay for on iHub is if you want additional features like private messaging, Level 2 and live streaming -- but some get those on their brokerage websites already.
    There are many free members, maybe most of them.

  • Just like what happened with ARIA when the decision came in very unexpectedly. When FDA feels pressure from citizen groups or supportive physicians etc. (AMRN has both on its petitions) it can especially help.

    And Zachs' research report emphasizes that Amarin is "pulling out all the stops" to get approval.

    Even with current level of sales IF the FDA didn't reverse decision, sales still merit a much higher price.

    Sentiment: Strong Buy

  • Reply to

    Wouldn't it be funny if the FDA...

    by keltus1952 Dec 28, 2013 1:59 AM
    lu.madar87 lu.madar87 Dec 28, 2013 4:50 AM Flag

    Here's how Zachs sums it up:

    The FDA will now view Amarin's appeal of the ANCHOR SPA agreement rescission and the ANCHOR sNDA separately. Amarin's request to reinstate the ANCHOR SPA agreement will be reviewed by FDA before Jan 15, 2014.

    We note that Vascepa, the only marketed product of the company, is already approved in the U.S. as an adjunct to diet for reducing triglyceride levels in adults suffering from severe hypertriglyceridemia (triglyceride ≥ 500mg/dL). Amarin refers to this as the MARINE indication. Amarin started marketing the drug in the U.S. in Jan 2013 and. reported $8.4 million in sales of Vascepa in the third quarter of 2013.

    Amarin is leaving no stone unturned to successfully commercialize Vascepa (MARINE indication) and expand the drug’s label into the ANCHOR indication.

  • Reply to

    Wouldn't it be funny if the FDA...

    by keltus1952 Dec 28, 2013 1:59 AM
    lu.madar87 lu.madar87 Dec 28, 2013 4:39 AM Flag

    That's what happened with ARIA last week -- you never know what management is doing behind the scenes and this company is described as "pulling out all the stops" to get approval...and now the old CEO is gone.
    -- Plus this stock has benefit of the investor-citizen petition which is credited with helping get the postponement, this has that extra going for it.
    -- I HOPE the bottom feeders trying to take it back down to where it was before last week get SCALDED.
    -- There seems to be a sense of worry being left out b/c last night's close at $1.82 was "painted" by some devious Market Marker: end of Day had crept back up to 1.85 then suddenly BAM taken down to the low in
    the last few minutes.

    Sentiment: Strong Buy

  • lu.madar87 lu.madar87 Dec 26, 2013 12:44 PM Flag

    Your guess is wrong as it always has been, done replying to you, we see where you're coming from and your lame efforts to deny just prove it.

    You either bought high and want to average down, or are being paid pennies to bash.
    Must be the latter because you are so rude you'd be self-hating to be Long, and doubt
    you can afford it. Also proved in other posts you're not much on spelling or math --
    you'll look even more foolish when you see the obvious from the numbers and Bid:Ask:
    this is the loading zone low and it goes higher and higher.

    Bye-bye, you can move on to bash the next one, you're done here.

    Sentiment: Strong Buy

  • lu.madar87 lu.madar87 Dec 26, 2013 12:29 PM Flag

    just a basher -- why??? short or paid??? Either way just ignore, this stock is being bought 5:1 sells today,
    this is the quiet post-Xmas week, low volume, last chance to load so cheap, back over $2.10 resistance soon, higher after Dec. tax-selling season is over and 1/15 nears

    Sentiment: Strong Buy

  • Reply to

    2.00 maybe today

    by rogermolettiere Dec 26, 2013 10:34 AM
    lu.madar87 lu.madar87 Dec 26, 2013 11:47 AM Flag

    Buys to sells 5:1 and bears are anxious to get in at today's lows judging by the volume of Bid:Ask it's clear: this post-Xmas period fo 2 days is their last chance to buy so cheap, back over $2.00 as support next week, min. $2.30-40 as 1/15 nears...should be over $3.00 after that.

    No wonder you're so anxious to grasp at straws you're making stuff up, swatchie!
    Buy while you can or lose your shorts.

    Sentiment: Strong Buy

  • Reply to

    1.50 to 2.00 to 1.50 to 2.00 33% swings!!!

    by bosle007 Dec 4, 2013 9:59 AM
    lu.madar87 lu.madar87 Dec 26, 2013 11:00 AM Flag

    you also missed spelling class.

    Whatever. Price is heading way UP as 1/15 nears, the shorts haven't been able to take it lower today however hard they've tried, even on low volume there's heavy loading.

    Sentiment: Strong Buy

JCP
10.23-0.54(-5.01%)Sep 19 4:05 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.